Antineoplastics and immunomodulators 2026-II Cytostatic drug containing the active ingredient avapritinib
A structured breakdown of scope, eligibility requirements, submission steps, and key conditions — extracted directly from the official notice.
Sign in to unlock Bid Fit & AI Opportunity Intelligence
TenderZenith calculates a personalized qualification score against your company profile and extracts structured intelligence from tender documents with your 7-Day Pro Trial (No Credit Card Required).
Contract Description
Antineoplastics and immunomodulators 2026-II Cytostatic drug containing the active ingredient avapritinib
After. form containing 25 mg of avapritinib per form unit, expected annual volume of 240 form units (doses); after. form containing 100 mg of avapritinib per form unit, estimated annual volume of 240 form units (doses); after. form containing 300 mg of avapritinib per form unit, expected annual volume of 120 form units (doses); ATC L01EX18
Related Procurement Opportunities
Similar tenders in Pharmaceuticals, Healthcare and Medicine, Chemicals